Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... by Claire M. Douglas (21238238)

Subjects:

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque count. by Francesca Catto (21253435)

“…Additionally, the plots on the right side display the average plaque count across the cohorts. …”

Summary of codes generated from MAXQDA software. by Awole Seid (3839965)

Subjects:

Schematic presentation of themes and categories. by Awole Seid (3839965)

Subjects:

Background characteristics of study participants. by Awole Seid (3839965)

Subjects:

Conceptual model derived from interpretations of findings. by Awole Seid (3839965)

Subjects:

Summary of key questions and follow-up probes used in the phenomenological study. by Awole Seid (3839965)

Subjects:

Dataset. by Awole Seid (3839965)

Subjects:

S1 File - by Luqiong Liu (11537092)

“…Compared with LPS treatment alone, BA significantly mitigated the reduction in the TEER, decreased FD-4 flux permeability, increased the mRNA expression of ZO-1 and Occludin, and normalized the distribution of ZO-1 and Occludin in Caco2 cells. …”

Experimental treatments and groups. by Luqiong Liu (11537092)

“…Compared with LPS treatment alone, BA significantly mitigated the reduction in the TEER, decreased FD-4 flux permeability, increased the mRNA expression of ZO-1 and Occludin, and normalized the distribution of ZO-1 and Occludin in Caco2 cells. …”

Primers for RT-qPCR. by Luqiong Liu (11537092)

“…Compared with LPS treatment alone, BA significantly mitigated the reduction in the TEER, decreased FD-4 flux permeability, increased the mRNA expression of ZO-1 and Occludin, and normalized the distribution of ZO-1 and Occludin in Caco2 cells. …”

Image 2_Changes of brain structure and structural covariance networks in Parkinson’s disease with different sides of onset.tif by Tianqi Xu (9574329)

“…Background<p>Parkinson’s disease (PD) typically presents with unilateral symptoms in early stages, starting on one side and progressing, with the onset side showing more severe motor symptoms even after bilateralization. …”

Image 1_Changes of brain structure and structural covariance networks in Parkinson’s disease with different sides of onset.tif by Tianqi Xu (9574329)

“…Background<p>Parkinson’s disease (PD) typically presents with unilateral symptoms in early stages, starting on one side and progressing, with the onset side showing more severe motor symptoms even after bilateralization. …”

Image 3_Changes of brain structure and structural covariance networks in Parkinson’s disease with different sides of onset.tif by Tianqi Xu (9574329)

“…Background<p>Parkinson’s disease (PD) typically presents with unilateral symptoms in early stages, starting on one side and progressing, with the onset side showing more severe motor symptoms even after bilateralization. …”

ONSD modifications induced by arterial paCO₂ changes. by Marco Carbonara (11483575)

Subjects: